IP Library Granted Patent US 10,280,157
Granted Patent B2
US 10,280,157 · App. 15/852,995 · Granted May 7, 2019

Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Inventors: Ming Tao (Maple Glen, PA); William Frietze (Kennett Square, PA); David J. Meloni (Bear, DE); Lingkai Weng (Phoenixville, PA); Jiacheng Zhou (Newark, DE); Yongchun Pan (Wilmington, DE)
Assignees: Incyte Corporation; Incyte Holdings Corporation
C07D413/04C07C307/06C07D271/04C07D271/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,280,157
App. No.
15/852,995
Granted
May 7, 2019
Kind
B2
Abstract

The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.

Claims (15)

1. A compound of Formula F16:

or a salt thereof, wherein:

each R 1 is independently an amino protecting group; and

R 3 is C 1-6 alkyl or benzyl.

2. The compound of claim 1 , or a salt thereof, wherein R 1 is C 2-4 alkenyl-C 1-3 alkyl or phenyl-C 1-3 alkyl, wherein said phenyl-C 1-3 alkyl is optionally substituted by 1, 2, or 3 independently selected C 1-4 alkoxy groups.

3. The compound of claim 1 , or a salt thereof, wherein R 1 is allyl.

4. The compound of claim 1 , or a salt thereof, wherein R 1 is 4-methoxybenzyl.

5. The compound of claim 1 , or a salt thereof, wherein R 3 is C 1-6 alkyl.

6. The compound of claim 1 , or a salt thereof, wherein R 3 is C 1-4 alkyl.

7. The compound of claim 1 , or a salt thereof, wherein R 3 is tert-butyl.

8. The compound of claim 1 , or a salt thereof, wherein R 3 is butyl.

9. The compound of claim 1 , wherein the compound of Formula F16 is tert-butyl allyl(N-allyl-N-(2-(4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-ylamino)ethyl)sulfamoyl)carbamate, or a salt thereof.

10. The compound of claim 1 , wherein the compound of Formula F16 is tert-butyl allyl(N-allyl-N-(2-(4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-ylamino)ethyl) sulfamoyl)carbamate.

11. The compound of claim 1 , wherein the compound of Formula F16 is tert-butyl (4-methoxybenzyl)-(N-(4-methoxybenzyl)-N-(2-(4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-ylamino)ethyl)sulfamoyl)carbamate, or a salt thereof.

12. The compound of claim 1 , wherein the compound of Formula F16 is tert-butyl (4-methoxybenzyl)-(N-(4-methoxybenzyl)-N-(2-(4-(4-(3-bromo-4-fluorophenyl)-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,2,5-oxadiazol-3-ylamino)ethyl)sulfamoyl)carbamate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2017
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 044497/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2017
From: TAO, MING; FRIETZE, WILLIAM; MELONI, DAVID J.; WENG, LINGKAI; ZHOU, JIACHENG; PAN, YONGCHUN
To: INCYTE CORPORATION
Reel/Frame 044486/0256 →
Continuity (4)
Continuation 15093486 · Apr 7, 2016
Continuation 14535781 · Nov 7, 2014
Provisional Application 61901689 · Nov 8, 2013
Related Publication 20180244663A1 · Aug 30, 2018